当前位置：药品说明书与价格首页 >> 糖尿病 >> 新药推荐 >> Xultophy（德谷胰岛素/利拉鲁肽复方注射预充/笔溶液）

Xultophy（德谷胰岛素/利拉鲁肽复方注射预充/笔溶液）

2014-12-22 19:42:32 作者：新特药房来源：互联网浏览次数：1285 文字大小：【大】【中】【小】

简介： 2014年9月21日，诺德糖尿病鸡尾酒Xultophy获欧盟批准，是全球首个长效胰岛素和GLP-1受体激动剂复方药，兼具降糖和减肥功效。Xultophy不仅显著改善了血糖水平，同时还提供了显著的减肥作用。Xultophy由T ...

关键字：德谷胰岛素/利拉鲁肽复方药 Tresiba（insulin degludec）+Victoza（liraglutide）药品商标名Xultophy 长效胰岛素和GLP-1受体激动剂糖尿病复方新药

2014年9月21日，诺德糖尿病鸡尾酒Xultophy获欧盟批准，是全球首个长效胰岛素和GLP-1受体激动剂复方药，兼具降糖和减肥功效。
Xultophy不仅显著改善了血糖水平，同时还提供了显著的减肥作用。Xultophy由Tresiba（insulin degludec，德谷胰岛素）和Victoza（liraglutide，利拉鲁肽）组成。Tresiba是一种长效基础胰岛素，Victoza则属于胰高血糖素样肽1（GLP-1）受体激动剂，能够刺激天然胰岛素分泌。

Xultophy 100 units/ml insulin degludec+3.6mg/mL liraglutide solution for injection in a pre-filled pen
1. Name of the medicinal product
Xultophy▼ 100 units/mL + 3.6 mg/mL solution for injection.
2. Qualitative and quantitative composition
1 mL solution contains 100 units insulin degludec* and 3.6 mg liraglutide*.
*Produced in Saccharomyces cerevisiae by recombinant DNA technology.
One pre-filled pen contains 3 mL equivalent to 300 units insulin degludec and 10.8 mg liraglutide.
One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Solution for injection.
Clear, colourless, isotonic solution.
4. Clinical particulars
4.1 Therapeutic indications
Xultophy is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).
4.2 Posology and method of administration
Posology
Xultophy is given once daily by subcutaneous administration. Xultophy can be administered at any time of the day, preferably at the same time of the day.
Xultophy is to be dosed in accordance with the individual patient's needs. It is recommended to optimise glycaemic control via dose adjustment based on fasting plasma glucose.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.
Patients who forget a dose are advised to take it upon discovery and then resume their usual once-daily dosing schedule. A minimum of 8 hours between injections should always be ensured. This also applies when administration at the same time of the day is not possible.
Xultophy is administered as dose steps. One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide. The pre-filled pen can provide from 1 up to 50 dose steps in one injection in increments of one dose step. The maximum daily dose of Xultophy is 50 dose steps (50 units insulin degludec and 1.8 mg liraglutide). The dose counter on the pen shows the number of dose steps.
Add-on to oral glucose lowering medicinal products
The recommended starting dose of Xultophy is 10 dose steps (10 units insulin degludec and 0.36 mg liraglutide).
Xultophy can be added to existing oral anti-diabetic treatment. When Xultophy is added to sulphonylurea therapy, a reduction in the dose of sulphonylurea should be considered (see section 4.4).
Transfer from basal insulin
Therapy with basal insulin should be discontinued prior to initiation of Xultophy. When transferring from basal insulin therapy, the recommended starting dose of Xultophy is 16 dose steps (16 units insulin degludec and 0.6 mg liraglutide) (see section 4.4 and 5.1). The recommended starting dose should not be exceeded. Close glucose monitoring is recommended during the transfer and in the following weeks.
Special populations
Elderly patients (≥ 65 years old)
Xultophy can be used in elderly patients. Glucose monitoring is to be intensified and the dose adjusted on an individual basis. The therapeutic experience in patients ≥75 years of age is limited.
Renal impairment
When Xultophy is used in patients with mild renal impairment, glucose monitoring is to be intensified and the dose adjusted on an individual basis. Xultophy cannot be recommended for use in patients with moderate or severe renal impairment including patients with end-stage renal disease (see section 5.2).
Hepatic impairment
The therapeutic experience with Xultophy in patients with hepatic impairment is currently too limited to recommend the use in these patients (see section 5.2).
Paediatric population
There is no relevant use of Xultophy in the paediatric population.
Method of administration
Xultophy is for subcutaneous use only. Xultophy must not be administered intravenously or intramuscularly.
Xultophy is administered subcutaneously by injection in the thigh, the upper arm or the abdomen. Injection sites are always to be rotated within the same region in order to reduce the risk of lipodystrophy. For further instructions on administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to either or both active substances or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Xultophy should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Hypoglycaemia
Hypoglycaemia may occur if the dose of Xultophy is higher than required. Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia. In combination with sulphonylurea, the risk of hypoglycaemia may be lowered by a reduction in the dose of sulphonylurea. Concomitant diseases in the kidney, liver or diseases affecting the adrenal, pituitary or thyroid gland may require changes of the Xultophy dose. Patients whose blood-glucose control is greatly improved (e.g. by intensified therapy) may experience a change in their usual warning symptoms of hypoglycaemia, and must be advised accordingly. Usual warning symptoms (see section 4.8) of hypoglycaemia may disappear in patients with long-standing diabetes. The prolonged effect of Xultophy may delay recovery from hypoglycaemia.
Hyperglycaemia
Inadequate dosing and/or discontinuation of anti-diabetic treatment may lead to hyperglycaemia and potentially to hyperosmolar coma. In case of discontinuation of Xultophy, ensure that instruction for initiation of alternative anti-diabetic medication is followed. Furthermore, concomitant illness, especially infections, may lead to hyperglycaemia and thereby cause an increased requirement for anti-diabetic treatment. Usually, the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, and loss of appetite as well as acetone odour of breath.
Administration of rapid-acting insulin should be considered in situations of severe hyperglycaemia. Untreated hyperglycaemic events eventually lead to hyperosmolar coma/diabetic ketoacidosis, which is potentially lethal.
Combination of pioglitazone and insulin medicinal products
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin medicinal products, especially in patients with risk factors for development of cardiac failure. This should be kept in mind if treatment with the combination of pioglitazone and Xultophy is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Eye disorder
Intensification of therapy with insulin, a component of Xultophy, with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Antibody formation
Administration of Xultophy may cause formation of antibodies against insulin degludec and/or liraglutide. In rare cases, the presence of such antibodies may necessitate adjustment of the Xultophy dose in order to correct a tendency to hyper- or hypoglycaemia. Very few patients developed insulin degludec specific antibodies, antibodies cross-reacting to human insulin or anti-liraglutide antibodies following treatment with Xultophy. Antibody formation has not been associated with reduced efficacy of Xultophy.
Acute pancreatitis
Use of GLP-1 receptor agonists including liraglutide, a component of Xultophy, has been associated with a risk of developing acute pancreatitis. There have been few reported events of acute pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Xultophy should be discontinued; if acute pancreatitis is confirmed, Xultophy should not be restarted. Caution should be exercised in patients with a history of pancreatitis.
Thyroid adverse events
Thyroid adverse events, including increased blood calcitonin, goitre and thyroid neoplasm have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, a component of Xultophy, in particular in patients with pre-existing thyroid disease, and Xultophy should therefore be used with caution.
Inflammatory bowel disease and diabetic gastroparesis
There is no experience with Xultophy in patients with inflammatory bowel disease and diabetic gastroparesis. Xultophy is therefore not recommended in these patients.
Dehydration
Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, a component of Xultophy. Patients treated with Xultophy should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.
Avoidance of medication errors
Patients must be instructed to always check the pen label before each injection to avoid accidental mix-ups between Xultophy and other injectable diabetes medicinal products.
Populations not studied
Transfer to Xultophy from doses of basal insulin > 40 units has not been studied.
Transfer from GLP-1 receptor agonists has not been studied.
Xultophy has not been studied in combination with dipeptidyl peptidase 4 (DPP-4) inhibitors, glinides or prandial insulin.
There is limited experience in patients with congestive heart failure New York Heart Association (NYHA) class I-II and Xultophy should therefore be used with caution. There is no experience in patients with congestive heart failure NYHA class III-IV and Xultophy is therefore not recommended in these patients.
Excipients
Xultophy contains less than 1 mmol sodium (23 mg) per dose, therefore the medicinal product is essentially 'sodium-free'.
4.5 Interaction with other medicinal products and other forms of interaction
Pharmacodynamic interactions
Interaction studies with Xultophy have not been performed.
A number of substances affect glucose metabolism and may require dose adjustment of Xultophy.
The following substances may reduce the Xultophy requirement:
Anti-diabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.
The following substances may increase the Xultophy requirement:
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormones and danazol.
Beta-blockers may mask the symptoms of hypoglycaemia.
Octreotide/lanreotide may either increase or decrease the Xultophy requirement.
Alcohol may intensify or reduce the hypoglycaemic effect of Xultophy.
Pharmacokinetic interactions
In vitro data suggest that the potential for pharmacokinetic drug interactions related to CYP interaction and protein binding is low for both liraglutide and insulin degludec.
The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products. Interaction studies did not show any clinically relevant delay of absorption.
Warfarin and other coumarin derivatives
No interaction study has been performed. A clinically relevant interaction with active substances with poor solubility or with narrow therapeutic index such as warfarin cannot be excluded. Upon initiation of Xultophy treatment in patients on warfarin or other coumarin derivatives more frequent monitoring of INR (International Normalised Ratio) is recommended.
Paracetamol
Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000 mg. Paracetamol Cmax was decreased by 31% and median tmax was delayed up to 15 min. No dose adjustment for concomitant use of paracetamol is required.
Atorvastatin
Liraglutide did not change the overall exposure of atorvastatin to a clinical relevant degree following single dose administration of atorvastatin 40 mg. Therefore, no dose adjustment of atorvastatin is required when given with liraglutide. Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.
Griseofulvin
Liraglutide did not change the overall exposure of griseofulvin following administration of a single dose of griseofulvin 500 mg. Griseofulvin Cmax increased by 37% while median tmax did not change. Dose adjustments of griseofulvin and other compounds with low solubility and high permeability are not required.
Digoxin
A single dose administration of digoxin 1 mg with liraglutide resulted in a reduction of digoxin AUC by 16%; Cmax decreased by 31%. Digoxin median time to maximum concentration (tmax) was delayed from 1 h to 1.5 h. No dose adjustment of digoxin is required based on these results.
Lisinopril
A single dose administration of lisinopril 20 mg with liraglutide resulted in a reduction of lisinopril AUC by 15%; Cmax decreased by 27%. Lisinopril median tmax was delayed from 6 h to 8 h with liraglutide. No dose adjustment of lisinopril is required based on these results.
Oral contraceptives
Liraglutide lowered ethinylestradiol and levonorgestrel Cmax by 12 and 13%, respectively, following administration of a single dose of an oral contraceptive product. Tmax was delayed by 1.5 h with liraglutide for both compounds. There was no clinically relevant effect on the overall exposure of either ethinylestradiol or levonorgestrel. The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.
4.6 Fertility, pregnancy and lactation
Pregnancy
There is no clinical experience with use of Xultophy, insulin degludec or liraglutide in pregnant women. If a patient wishes to become pregnant, or pregnancy occurs, treatment with Xultophy should be discontinued.
Animal reproduction studies with insulin degludec have not revealed any differences between insulin degludec and human insulin regarding embryotoxicity and teratogenicity. Animal studies with liraglutide have shown reproductive toxicity, see section 5.3. The potential risk for humans is unknown.
Breast-feeding
There is no clinical experience with use of Xultophy during breast-feeding. It is not known whether insulin degludec or liraglutide is excreted in human milk. Because of lack of experience, Xultophy should not be used during breast-feeding.
In rats, insulin degludec was secreted in milk; the concentration in milk was lower than in plasma. Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk was low. Non-clinical studies with liraglutide have shown a treatment-related reduction of neonatal growth in suckling rat pups (see section 5.3).
Fertility
There is no clinical experience with Xultophy on fertility.
Animal reproduction studies with insulin degludec have not revealed any adverse effects on fertility. Apart from a slight decrease in the number of live implants, animal studies with liraglutide did not indicate harmful effects with respect to fertility.
4.7 Effects on ability to drive and use machines
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
Patients must be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.
4.8 Undesirable effects
Summary of the safety profile
The Xultophy clinical development programme included approximately 1,300 patients treated with Xultophy.
The most frequently reported adverse reactions during treatment with Xultophy were hypoglycaemia and gastrointestinal adverse reactions (see section 'Description of selected adverse reactions' below).
Tabulated list of adverse reactions
Adverse reactions associated with Xultophy are given below, listed by system organ class and frequency. Frequency categories are defined as: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Table 1 Adverse reactions reported in phase 3 controlled studies

System organ class

Frequency

Adverse Drug Reaction

Immune system disorders

Uncommon

Urticaria

Rare

Hypersensitivity

Unknown

Anaphylactic reaction

Metabolism and nutrition disorders

Very common

Hypoglycaemia

Common

Decreased appetite

Uncommon

Dehydration

Gastrointestinal disorders

Common

Nausea, diarrhoea, vomiting, constipation, dyspepsia, gastritis, abdominal pain, flatulence, gastroesophageal reflux disease, abdominal distension

Unknown

Pancreatitis (including necrotising pancreatitis )

Skin and subcutaneous tissue disorders

Uncommon

Rash

Uncommon

Pruritus

Rare

Lipodystrophy acquired

General disorders and administration site condition

Common

Injection site reaction

Unknown

Peripheral oedema

Investigation

Uncommon

Increased heart rate
Description of selected adverse reactions
Hypoglycaemia
Hypoglycaemia may occur if the Xultophy dose is higher than required. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation. For frequencies of hypoglycaemia, please see section 5.1.
Allergic reactions
Allergic reactions (manifested with signs and symptoms such as urticaria (0.3% of patients treated with Xultophy), rash (0.8%), pruritus (0.6%) and/or swelling of face (0.2%)) have been reported for Xultophy. Few cases of anaphylactic reactions with additional symptoms such as hypotension, palpitations, dyspnoea, and oedema have been reported during marketed use of liraglutide. Anaphylactic reactions may potentially be life threatening.
Gastrointestinal adverse reactions
Gastrointestinal adverse reactions may occur more frequently at the beginning of Xultophy therapy and usually diminish within a few days or weeks on continued treatment. Nausea was reported in 8.5% of patients and was transient in nature for most patients. The proportion of patients reporting nausea per week at any point during treatment was below 4%. Diarrhoea and vomiting were reported in 8.3% and 4.2% of patients, respectively. The frequency of nausea and diarrhoea was 'Common' for Xultophy and 'Very common' for liraglutide. In addition, constipation, dyspepsia, gastritis, abdominal pain, flatulence, gastroesophageal reflux disease, abdominal distension and decreased appetite have been reported in up to 3.6% of patients treated with Xultophy.
Injection site reactions
Injection site reactions (including injection site haematoma, pain, haemmorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) have been reported in 3.0% of patients treated with Xultophy. These reactions were usually mild and transitory and they normally disappear during continued treatment.
Lipodystrophy
Lipodystrophy (including lipohypertrophy, lipoatrophy) may occur at the injection site. Continuous rotation of the injection site within the particular injection area may help to reduce the risk of developing these reactions.
Increased heart rate
Mean increase in heart rate from baseline of 2 to 3 beats per minute has been observed in clinical trials with Xultophy. The long-term clinical effects of the increase in heart rate have not been established.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
Ireland
HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie
4.9 Overdose
Limited data are available with regard to overdose of Xultophy.
Hypoglycaemia may develop if a patient is dosed with more Xultophy than required:
• Mild hypoglycaemic episodes can be treated by oral administration of glucose or other products containing sugar. It is therefore recommended that the patient always carries sugar-containing products
• Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: not yet assigned. ATC code not yet assigned
Mechanism of action
Xultophy is a combination product consisting of insulin degludec and liraglutide having complementary mechanisms of action to improve glycaemic control.
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering-effect of insulin degludec with a low day-to-day variability in insulin action.
Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin.
The blood glucose-lowering effect of insulin degludec is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.
Liraglutide is a Glucagon-Like Peptide-1 (GLP-1) analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. Following subcutaneous administration, the protracted action profile is based on three mechanisms: self-association, which results in slow absorption; binding to albumin; and higher enzymatic stability towards the dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP) enzymes, resulting in a long plasma half-life.
Liraglutide action is mediated via a specific interaction with GLP-1 receptors and improves glycaemic control by lowering fasting and postprandial blood glucose. Liraglutide stimulates insulin secretion and lowers inappropriately high glucagon secretion in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. Conversely, during hypoglycaemia liraglutide diminishes insulin secretion and does not impair glucagon secretion. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying. Liraglutide reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake.
Pharmacodynamic effects
Xultophy has a stable pharmacodynamic profile with a duration of action reflecting the combination of the individual action profiles of insulin degludec and liraglutide that allows for administration of Xultophy once daily at any time of the day with or without meals. Xultophy improves glycaemic control through the sustained lowering of fasting plasma glucose levels and postprandial glucose levels after all meals.
Postprandial glucose reduction was confirmed in a 4 hour standardised meal test sub-study in patients uncontrolled on metformin alone or in combination with pioglitazone. Xultophy decreased the postprandial plasma glucose excursion (mean over 4 hours) significantly more than insulin degludec. The results were similar for Xultophy and liraglutide.
Clinical efficacy and safety
Add-on to oral glucose lowering medicinal products
Add-on to metformin alone or in combination with pioglitazone
The efficacy and safety of Xultophy compared to insulin degludec and liraglutide, all once daily, were studied in a 26-week randomised, controlled, open-label, treat-to-target trial in patients with type 2 diabetes mellitus with a 26 week extension. The starting dose of Xultophy and insulin degludec was 10 dose steps (10 units insulin degludec and 0.36 mg liraglutide) and 10 units, respectively, and the dose was titrated twice weekly according to Table 2 below.
Patients in the liraglutide arm followed a fixed dose escalation scheme with a starting dose of 0.6 mg and a dose increase of 0.6 mg weekly until the maintenance dose of 1.8 mg was reached. The maximum dose of Xultophy was 50 dose steps, while there was no maximum dose in the insulin degludec arm.
Table 2 Titration of Xultophy and insulin degludec

Pre-breakfast plasma glucose*

Dose adjustment

mmol/L

mg/dL

Xultophy (dose steps)

insulin degludec (units)

< 4.0

< 72

-2

-2

4.0-5.0

72-90

0

0

> 5.0

> 90

+2

+2
*Self-measured plasma glucose
The key results of the trial are listed in Figure 1 and Table 3.
60.4% of patients treated with Xultophy reached a target of HbA1c <7% without confirmed hypoglycaemic episodes after 26 weeks of treatment. The proportion was significantly larger than observed with insulin degludec (40.9%) and similar to that observed with liraglutide (57.7%).
Rates of confirmed hypoglycaemia were lower with Xultophy than with insulin degludec irrespective of the glycaemic control, see Figure 1.

IDegLira=Xultophy, IDeg=insulin degludec, Lira=liraglutide, obs. rate=observed rate, PYE=patient year of exposure
Figure 1 Mean HbA1c (%) by treatment week (left) and rate of confirmed hypoglycaemia per patient year of exposure vs mean HbA1c (%) (right) in patients with type 2 diabetes mellitus inadequately controlled on metformin alone or in combination with pioglitazone
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia defined as an episode requiring assistance of another person was 0.01 (2 patients out of 825) for Xultophy, 0.01 (2 patients out of 412) for insulin degludec and 0.00 (0 patients out of 412) for liraglutide. The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.
Patients treated with Xultophy overall experienced less gastrointestinal side effects than patients treated with liraglutide. This might be due to the slower increase in the dose of the liraglutide component during treatment initiation when using Xultophy as compared to using liraglutide alone.
Long-term (52 week) data in patients inadequately controlled on metformin alone or in combination with pioglitazone
The efficacy and safety of Xultophy were sustained up to 52 weeks of treatment. The reduction in HbA1c from baseline to 52 weeks was 1.84% with Xultophy with an estimated treatment difference of -0.65% compared to liraglutide (p<0.0001) and -0.46% compared to insulin degludec (p<0.0001). Body weight was reduced by 0.4 kg with an estimated treatment difference between Xultophy and insulin degludec of -2.80 kg (p<0.0001), and the rate of confirmed hypoglycaemia remained 1.8 events per patient year of exposure maintaining a significant reduction in overall risk of confirmed hypoglycaemia compared to insulin degludec.
Add-on to sulphonylurea alone or in combination with metformin
The efficacy and safety of Xultophy as add-on to sulphonylurea alone or in combination with metformin were studied in a 26-week randomised, placebo-controlled, double-blind, treat-to-target trial in 435 patients with type 2 diabetes mellitus of which 289 were treated with Xultophy. The starting dose of Xultophy was 10 dose steps (10 units insulin degludec and 0.36 mg liraglutide), and the dose was titrated twice weekly. Titration was performed as outlined in Table 2 though with a titration target of 4-6 mmol/L.
The key results or the trial are listed in Figure 2 and Table 3.

IDegLira=Xultophy
Figure 2 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulphonylurea alone or in combination with metformin
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.02 (2 patients out of 288) for Xultophy and 0.00 (0 patients out of 146) for placebo.
Table 3 Results from 26 week trials with Xultophy in patients with type 2 diabetes mellitus either inadequately controlled on metformin alone or in combination with pioglitazone (left) or inadequately controlled on sulphonylurea alone or in combination with metformin (right)

Previous treatment with metformin±pioglitazone

Previous treatment with sulphonylurea ± metformin

Xultophy

Insulin degludec

Liraglutide

Xultophy

Placebo

N

833

413

414

289

146

HbA_1c(%)
Baseline→End of trial
Mean change
Estimated difference

8.3→6.4
-1.91

8.3→6.9
-1.44
-0.47^AB[-0.58; -0.36]

8.3→7.0
-1.28
-0.64^AB[-0.75; -0.53]

7.9→6.4
-1.45

7.9→7.4
-0.46
-1.02^AB[-1.18; -0.87]

Patients (%) achieving HbA_1c <7%
All patients
Estimated odds ratio

80.6

65.1
2.38^B [1.78;3.18]

60.4
3.26^B [2.45; 4.33]

79.2

28.8
11.95^B [7.22; 19.77]

Patients (%) achieving HbA_1c≤ 6.5%
All patients
Estimated odds ratio

69.7

47.5
2.82^B [2.17;3.67]

41.1
3.98^B [3.05; 5.18]

64.0

12.3
16.36^B [9.05; 29.56]

Rate of confirmed hypoglycaemia* per patient year of exposure (percentage of patients)
Estimated ratio

1.80 (31.9%)

2.57 (38.6%)
0.68^AC [0.53; 0.87]

0.22 (6.8%)
7.61^B [5.17; 11.21]

3.52 (41.7%)

1.35 (17.1%)
3.74^B [2.28; 6.13]

Body Weight (kg)
Baseline→End of trial
Mean change
Estimated difference

87.2→86.7
-0.5

87.4→89.0
1.6
-2.22^AB [-2.64; -1.80]

87.4→84.4
-3.0
2.44^B [2.02; 2.86]

87.2→87.7
0.5

89.3→88.3
-1.0
1.48^B [0.90; 2.06]

FPG (mmol/L)
Baseline→End of trial
Mean change
Estimated difference

9.2→5.6
-3.62

9.4→5.8
-3.61
-0.17 [-0.41; 0.07]

9.0→7.3
-1.75
-1.76^B [2.0; -1.53]

9.1→6.5
-2.60

9.1→8.8
-0.31
-2.30^B [-2.72; -1.89]

Dose End of trial
Insulin degludec (units)
Liraglutide (mg)
Estimated difference, insulin degludec dose

38
1.4

53
-
-14.90^AB [-17.14;
-12.66]

-
1.8

28
1.0

-
-
-
Baseline, End of trial and change values are observed Last observation carried forward. The 95% confidence interval is stated in '[]'
*Confirmed hypoglycaemia defined as severe hypoglycaemia (episode requiring assistance of another person) and/or minor hypoglycaemia (plasma glucose <3.1 mmol/L irrespective of symptoms)
A Endpoints with confirmed superiority of Xultophy vs comparator
B p<0.0001
C p<0.05
Transfer from basal insulin therapy
The efficacy and safety of Xultophy compared to insulin degludec, both once daily, were studied in a 26-weeks randomised, double-blind, treat-to-target trial in patients with type 2 diabetes mellitus inadequately controlled on basal insulin (20–40 units) and metformin alone or in combination with sulphonylurea/glinides. Basal insulin and sulphonylurea/glinides were discontinued at randomisation.
The starting dose of Xultophy and insulin degludec was 16 dose steps (16 units insulin degludec and 0.6 mg liraglutide) and 16 units, respectively, and the dose was titrated twice weekly according to Table 2. The maximum allowed dose was 50 dose steps for Xultophy and 50 units for insulin degludec.
The key results of the trial are listed in Table 4 and Figure 3.
Table 4 Results of a 26 week trial with Xultophy in patients with type 2 diabetes mellitus inadequately controlled on basal insulin

Previous treatment with basal insulin

Xultophy

Insulin degludec
Maximum dose 50 units

N

199

199

HbA_1c(%)
Baseline→End of trial
Mean change
Estimated difference

8.7→6.9
-1.90

8.8→8.0
-0.89
-1.05^AB[-1.25; -0.84]

Patients (%) achieving HbA_1c <7%
All patients
Estimated odds ratio

60.3

23.1
5.44^B [3.42; 8.66]

Patients (%) achieving HbA_1c≤6.5%
All patients
Estimated odds ratio

45.2

13.1
5.66^B [3.37; 9.51]

Rate of confirmed hypoglycaemia* per patient year of exposure (percentage of patients)
Estimated ratio

1.53 (24.1%)

2.63 (24.6%)
0.66 [0.39; 1.13]

Body Weight (kg)
Baseline→End of trial
Mean change
Estimated difference

95.4→92.7
-2.7

93.5→93.5
0.0
-2.51^B [-3.21; -1.82]

FPG (mmol/L)
Baseline→End of trial
Mean change
Estimated difference

9.7→6.2
-3.46

9.6→7.0
-2.58
-0.73^C [-1.19; -0.27]

Dose End of trial
Insulin degludec (units)
Liraglutide (mg)
Estimated difference, insulin degludec dose

45
1.7

45
-
-0.02 [-1.88; 1.84]
Baseline, End of trial and change values are observed Last observation carried forward. The 95% confidence interval is stated in '[]'
*Confirmed hypoglycaemia defined as severe hypoglycaemia (episode requiring assistance of another person) and/or minor hypoglycaemia (plasma glucose<3.1 mmol/L irrespective of symptoms)
A Endpoints with confirmed superiority of Xultophy vs comparator
B p<0.0001
C p<0.05
48.7% of patients reached the HbA1c target of <7% without confirmed hypoglycaemic episodes, which was a significantly higher proportion than observed with insulin degludec (15.6%).

IDegLira=Xultophy, IDeg=insulin degludec
Figure 3 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on basal insulin
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 199) for Xultophy and 0.00 (0 patients out of 199) for insulin degludec. The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.
Other clinical data
Insulin secretion/beta-cell function
Xultophy improves beta-cell function compared to insulin degludec as measured by the homeostasis model assessment for beta-cell function (HOMA-β). Improved insulin secretion compared to insulin degludec in response to a standardised meal test was demonstrated in 260 patients with type 2 diabetes after 52 weeks treatment. No data is available beyond 52 weeks of treatment.
Blood pressure
In patients inadequately controlled on metformin alone or in combination with pioglitazone, Xultophy reduced mean systolic blood pressure by 1.8 mmHg compared to a reduction of 0.7 mmHg with insulin degludec and 2.7 mmHg with liraglutide. In patients inadequately controlled on sulphonylurea alone or in combination with metformin, the reduction was 3.5 mmHg with Xultophy and 3.2 mmHg with placebo. The differences were not statiscally significant. In patients inadequately controlled on basal insulin, the reduction in mean systolic blood pressure was 5.4 mmHg with Xultophy and 1.7 mmHg with insulin degludec, with a statistically significant estimated treatment difference of -3.71 mmHg (p=0.0028).
Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with Xultophy in all subsets of the paediatric population in treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties
Overall, the pharmacokinetics of insulin degludec and liraglutide were not affected in a clinically relevant manner when administered as Xultophy compared with independent injections of insulin degludec and liraglutide.
The following reflects the pharmacokinetic properties of Xultophy unless stated that the presented data is from administration of insulin degludec or liraglutide alone.
Absorption
The overall exposure of insulin degludec was equivalent following administration of Xultophy versus insulin degludec alone while the Cmax was higher by 12%. The overall exposure of liraglutide was equivalent following administration of Xultophy versus liraglutide alone while Cmax was lower by 23%. The differences are considered of no clinical relevance since Xultophy is initiated and titrated according to the individual patient's blood glucose targets.
Insulin degludec and liraglutide exposure increased proportionally with the Xultophy dose within the full dose range based on a population pharmacokinetic analysis.
The pharmacokinetic profile of Xultophy is consistent with once daily dosing and steady state concentration of insulin degludec and liraglutide is reached after 2–3 days of daily administration.
Distribution
Insulin degludec and liraglutide are extensively bound to plasma proteins (> 99% and > 98%, respectively).
Biotransformation
Insulin degludec
Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.
Liraglutide
During 24 hours following administration of a single radiolabelled [3H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide. Two minor plasma metabolites were detected (≤ 9% and ≤ 5% of total plasma radioactivity exposure). Liraglutide is metabolised in a similar manner to large proteins without a specific organ having been identified as major route of elimination.
Elimination
The half-life of insulin degludec is approximately 25 hours and the half-life of liraglutide is approximately 13 hours.
Special populations
Elderly patients
Age had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including adult patients up to 83 years treated with Xultophy.
Gender
Gender had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis.
Ethnic origin
Ethnic origin had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including White, Black, Indian, Asian and Hispanic groups.
Renal impairment
Insulin degludec
There is no difference in the pharmacokinetics of insulin degludec between healthy subjects and patients with renal impairment.
Liraglutide
Liraglutide exposure was reduced in subjects with renal impairment compared to individuals with normal renal function. Liraglutide exposure was lowered by 33%, 14%, 27% and 28%, respectively, in subjects with mild (creatinine clearance, CrCl 50–80 mL/min), moderate (CrCl 30–50 mL/min), and severe (CrCl < 30 mL/min) renal impairment and in end-stage renal disease requiring dialysis.
Hepatic impairment
Insulin degludec
There is no difference in the pharmacokinetics of insulin degludec between healthy subjects and patients with hepatic impairment.
Liraglutide
The pharmacokinetics of liraglutide was evaluated in subjects with varying degrees of hepatic impairment in a single-dose trial. Liraglutide exposure was decreased by 13–23% in subjects with mild to moderate hepatic impairment compared to healthy subjects. Exposure was significantly lower (44%) in subjects with severe hepatic impairment (Child Pugh score > 9).
Paediatric population
No studies have been performed with Xultophy in children and adolescents below 18 years of age.
5.3 Preclinical safety data
The non-clinical development programme for insulin degludec/liraglutide included pivotal combination toxicity studies of up to 90 days duration in a single relevant species (Wistar rats) to support the clinical development programme. Local tolerance was assessed in rabbits and pigs.
Non-clinical safety data revealed no safety concern for humans based on repeated dose toxicity studies.
The local tissue reactions in the two studies in rabbits and pigs, respectively, were limited to mild inflammatory reactions.
No studies have been conducted with the insulin degludec/liraglutide combination to evaluate carcinogenesis, mutagenesis or impairment of fertility. The following data are based upon studies with insulin degludec and liraglutide individually.
Insulin degludec
Non-clinical data reveal no safety concern for humans based on studies of safety pharmacology, repeated dose toxicity, carcinogenic potential, and toxicity to reproduction.
The ratio of mitogenic relative to metabolic potency for insulin degludec is unchanged compared to human insulin.
Liraglutide
Non-clinical data reveal no special hazards for human based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity. Non-lethal thyroid C-cell tumours were seen in 2-year carcinogenicity studies in rats and mice. In rats, a no observed adverse effect level (NOAEL) was not observed. These tumours were not seen in monkeys treated for 20 months. These findings in rodents are caused by a non-genotoxic, specific GLP-1 receptor-mediated mechanism to which rodents are particularly sensitive. The relevance for humans is likely to be low but cannot be completely excluded. No other treatment-related tumours have been found.
Animal studies did not indicate direct harmful effects with respect to fertility but slightly increased early embryonic deaths at the highest dose. Dosing with liraglutide during mid-gestation caused a reduction in maternal weight and foetal growth with equivocal effects on ribs in rats and skeletal variation in the rabbit. Neonatal growth was reduced in rats while exposed to liraglutide, and persisted in the post-weaning period in the high dose group. It is unknown whether the reduced pup growth is caused by reduced pup milk intake due to a direct GLP-1 effect or reduced maternal milk production due to decreased caloric intake.
6. Pharmaceutical particulars
6.1 List of excipients
Glycerol
Phenol
Zinc acetate
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
6.2 Incompatibilities
Substances added to Xultophy may cause degradation of the active substances.
Xultophy must not be added to infusion fluids.
This medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
2 years.
After first opening, the product can be stored for 21 days at a maximum temperature of 25°C. The product should be discarded 21 days after first opening.
6.4 Special precautions for storage
Before first opening: Store in a refrigerator (2°C – 8°C). Keep away from the freezing element. Do not freeze. Keep the cap on the pre-filled pen in order to protect from light.
After first opening: Store below 25°C or store in a refrigerator (2°C – 8°C). Do not freeze. Keep the cap on the pre-filled pen in order to protect from light.
For storage conditions after first opening of the medicinal product, see section 6.3.
6.5 Nature and contents of container
3 mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a stopper (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polycarbonate and acrylonitrile butadiene styrene.
Pack sizes of 1, 3, 5 and multipack containing 10 (2 packs of 5) pre-filled pens.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
The pre-filled pen is designed to be used with NovoTwist or NovoFine injection needles up to a length of 8 mm and as thin as 32G.
The pre-filled pen is for use by one person only.
Xultophy must not be used if the solution does not appear clear and colourless.
Xultophy which has been frozen must not be used.
The patient should discard the needle after each injection.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
For detailed instructions for use, see the package leaflet.
7. Marketing authorisation holder
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
8. Marketing authorisation number(s)
EU/1/14/947/001
EU/1/14/947/002
EU/1/14/947/003
EU/1/14/947/004
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation: 18 September 2014
10. Date of revision of the text
09/2014
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
糖尿病复方新药Xultophy(利拉鲁肽/德谷胰岛素)获欧盟批准
诺和诺德（Novo Nordisk）的糖尿病复方新药Xultophy®（IDegLira）近日获欧盟批准，用于2型糖尿病成人患者的治疗。Xultophy是首个长效胰岛素和GLP-1受体激动剂复方药，临床试验中，Xultophy不仅显著改善了血糖水平，同时还提供了显著的减肥作用。Xultophy由德谷胰岛素（Tresiba®）和利拉鲁肽（Victoza®）组成。德谷胰岛素是一种长效基础胰岛素，利拉鲁肽则属于胰高血糖素样肽1（GLP-1）受体激动剂，能够刺激天然胰岛素分泌。
去年，FDA因心血管风险拒绝批准德谷胰岛素，并告知诺和诺德，在提交长期预后数据证明德谷胰岛素安全性之前，不能重新提交德谷胰岛素的上市申请。诺和诺德预测，德谷胰岛素到2017年才会在美国上市。另外，根据FDA要求，任何复方产品必须由2种或更多已获批的药物组成，因此Xultophy何时登陆美国尚不得而知。
利拉鲁肽是诺和诺德的重磅药物，年销售额高达20亿美元，在GLP-1市场中傲视群雄。业界预测，Xultophy年销售峰值将突破10亿美元，该药又将成为诺和诺德的下一个重磅产品。但Tresiba何时获FDA批准尚无时间表，因此难以确定Xeltophy的真正潜力，但有一点毫无疑问，Xultophy的前途不可限量！
糖尿病新药开发已成为生物技术领域的重点，GLP-1受体激动剂尤受关注。目前，GLP-1领域竞争日益激烈，已上市的有诺和诺德的利拉鲁肽（liraglutide, Victoza®, 每日1次），百时美施贵宝和阿斯利康的艾塞那肽（exenatide, Byetta®, 每日2次）和长效缓释艾塞那肽（Bydureon®, 每周一次），赛诺菲的利西拉肽（lixisenatide, Lyxumia®, 每日1次），葛兰素史克的阿必鲁肽（albiglutide, Tanzeum®/Eperzan®, 每周1次）。
FDA刚刚批准礼来（Lilly）糖尿病新药度拉鲁肽（dulaglutide, Trulicity®, 每周1次）（见 FDA批准dulaglutide注射剂用于治疗2型糖尿病）该药也属于GLP-1受体激动剂，临床试验中与诺和诺德利拉鲁肽疗效相当，但利拉鲁肽每日注射一次，而度拉鲁肽每周注射一次更具优势，这将成为礼来营销时的卖点，该药将成为利拉鲁肽的替代者.